REVIEW ARTICLE
Research progress of malignant peritoneal mesothelioma with paraneoplastic syndrome: A review
Xin-Li Liang,
Xin-Bao Li,
Yu-Bin Fu,
Yan-Dong Su,
Ru Ma,
Rui Yang,
He-Liang Wu,
Yan Li MD, PhD,
Xin-Li Liang
Department of Peritoneal Cancer Surgery, Beijing Shijitan Hospital, Capital Medical University, Beijing, China
Search for more papers by this authorXin-Bao Li
Department of Peritoneal Cancer Surgery, Beijing Shijitan Hospital, Capital Medical University, Beijing, China
Search for more papers by this authorYu-Bin Fu
Department of Peritoneal Cancer Surgery, Beijing Shijitan Hospital, Capital Medical University, Beijing, China
Search for more papers by this authorYan-Dong Su
Department of Peritoneal Cancer Surgery, Beijing Shijitan Hospital, Capital Medical University, Beijing, China
Search for more papers by this authorRu Ma
Department of Peritoneal Cancer Surgery, Beijing Shijitan Hospital, Capital Medical University, Beijing, China
Search for more papers by this authorRui Yang
Department of Peritoneal Cancer Surgery, Beijing Shijitan Hospital, Capital Medical University, Beijing, China
Search for more papers by this authorHe-Liang Wu
Department of Peritoneal Cancer Surgery, Beijing Shijitan Hospital, Peking University Ninth School of Clinical Medicine, Beijing, China
Search for more papers by this authorCorresponding Author
Yan Li MD, PhD
Department of Peritoneal Cancer Surgery, Beijing Shijitan Hospital, Capital Medical University, Beijing, China
Department of Surgical Oncology, Beijing Tsinghua Changgung Hospital, Tsinghua University, Beijing, China
Correspondence Yan Li, MD, PhD, Department of Peritoneal Cancer Surgery, Beijing Shijitan Hospital, Capital Medical University, No. 10 Tieyi Rd, Yangfangdian St, Haidian District, Beijing, 100038, China.
Email: [email protected]
Search for more papers by this authorXin-Li Liang,
Xin-Bao Li,
Yu-Bin Fu,
Yan-Dong Su,
Ru Ma,
Rui Yang,
He-Liang Wu,
Yan Li MD, PhD,
Xin-Li Liang
Department of Peritoneal Cancer Surgery, Beijing Shijitan Hospital, Capital Medical University, Beijing, China
Search for more papers by this authorXin-Bao Li
Department of Peritoneal Cancer Surgery, Beijing Shijitan Hospital, Capital Medical University, Beijing, China
Search for more papers by this authorYu-Bin Fu
Department of Peritoneal Cancer Surgery, Beijing Shijitan Hospital, Capital Medical University, Beijing, China
Search for more papers by this authorYan-Dong Su
Department of Peritoneal Cancer Surgery, Beijing Shijitan Hospital, Capital Medical University, Beijing, China
Search for more papers by this authorRu Ma
Department of Peritoneal Cancer Surgery, Beijing Shijitan Hospital, Capital Medical University, Beijing, China
Search for more papers by this authorRui Yang
Department of Peritoneal Cancer Surgery, Beijing Shijitan Hospital, Capital Medical University, Beijing, China
Search for more papers by this authorHe-Liang Wu
Department of Peritoneal Cancer Surgery, Beijing Shijitan Hospital, Peking University Ninth School of Clinical Medicine, Beijing, China
Search for more papers by this authorCorresponding Author
Yan Li MD, PhD
Department of Peritoneal Cancer Surgery, Beijing Shijitan Hospital, Capital Medical University, Beijing, China
Department of Surgical Oncology, Beijing Tsinghua Changgung Hospital, Tsinghua University, Beijing, China
Correspondence Yan Li, MD, PhD, Department of Peritoneal Cancer Surgery, Beijing Shijitan Hospital, Capital Medical University, No. 10 Tieyi Rd, Yangfangdian St, Haidian District, Beijing, 100038, China.
Email: [email protected]
Search for more papers by this authorFirst published: 31 July 2024
Abstract
Malignant peritoneal mesothelioma (MPM) is a rare and invasive tumor, and some patients will develop paraneoplastic syndrome (PS) during the course of the disease. This review summarizes PS associated with MPM, focusing on the clinical characteristics and treatment progress in hematological, endocrine, rheumatic, neurological, urinary, and other systems to decrease missed diagnosis and misdiagnosis, help early diagnosis and prompt treatment, and provide guidance for the clinical decision-making of this kind of patients.
CONFLICT OF INTEREST STATEMENT
The authors declare no conflict of interest.
Open Research
DATA AVAILABILITY STATEMENT
The datasets were collected and summarized scientifically from the available literature. No new data were created or analyzed in this study; therefore, data sharing is not applicable to this article. However, the data in the form of tables and figures created during the review preparation are available from the corresponding author on reasonable request.
REFERENCES
- 1Calthorpe L, Romero-Hernandez F, Miller P, et al. Contemporary trends in malignant peritoneal mesothelioma: incidence and survival in the United States. Cancers (Basel). 2022; 15(1):229.
- 2Broeckx G, Pauwels P. Malignant peritoneal mesothelioma: a review. Transl Lung Cancer Res. 2018; 7(5): 537-542.
- 3Malpica A, Euscher ED, Marques-Piubelli ML, et al. Malignant mesothelioma of the peritoneum in women: a clinicopathologic study of 164 cases. Am J Surg Pathol. 2021; 45(1): 45-58.
- 4Malpica A. Peritoneal mesothelioma—an update. Adv Anat Pathol. 2023; 30(4): 262-274.
- 5Pelosof LC, Gerber DE. Paraneoplastic syndromes: an approach to diagnosis and treatment. Mayo Clin Proc. 2010; 85(9): 838-854.
- 6Manzini VP, Recchia L, Cafferata M, et al. Malignant peritoneal mesothelioma: a multicenter study on 81 cases. Ann Oncol. 2010; 21(2): 348-353.
- 7Li YC, Khashab T, Terhune J, et al. Preoperative thrombocytosis predicts shortened survival in patients with malignant peritoneal mesothelioma undergoing operative cytoreduction and hyperthermic intraperitoneal chemotherapy. Ann Surg Oncol. 2017; 24(8): 2259-2265.
- 8Üstündağ Y, Can U, Benli S, Büyükasik Y, Özbek N. Internal carotid artery occlusion in a patient with malignant peritoneal mesothelioma: is it a sign of malignancy-related thrombosis? Am J Med Sci. 2000; 319(4): 265-267.
- 9Nguyen D, Lee SJ, Libby E, Verschraegen C. Rate of thromboembolic events in mesothelioma. Ann Thorac Surg. 2008; 85(3): 1032-1038.
- 10Socola F, Loaiza-Bonilla A, Bustinza-Linares E, Correa R, Rosenblatt JD. Recurrent thrombotic thrombocytopenic purpura-like syndrome as a paraneoplastic phenomenon in malignant peritoneal mesothelioma: a case report and review of the literature. Case Rep Oncol Med. 2012; 2012: 1-5.
- 11Dynkevich Y, Rother KI, Whitford I, et al. Tumors, IGF-2, and hypoglycemia: insights from the clinic, the laboratory, and the historical archive. Endocr Rev. 2013; 34(6): 798-826.
- 12Losada López I, Nicolau Ramis JA, Gómez Gómez LA, Rodríguez Rodríguez I, Masmiquel Comas L. Glucagon perfusion in paraneoplastic hypoglycemia. Endocrinol Nutr. 2009; 56(3): 143-146.
- 13Mendoza CF, Ontiveros P, Xibillé DX, Rivera MH. Ectopic ACTH secretion (EAS) associated to a well-differentiated peritoneal mesothelioma: case report. BMC Endocr Disord. 2015; 15:40.
- 14Ozkan M, Eser B, Er O, et al. Antiphospholipid syndrome associated with malignant mesothelioma presenting with superior vena cava thrombosis: a case report. Clin Appl Thromb Hemost. 2004; 10(4): 393-396.
- 15Ide Y, Yuki T, Taooka Y, Higashi Y, Tachiyama Y. Malignant peritoneal mesothelioma presenting with polymyalgia rheumatica-like syndrome. Intern Med. 2020; 59(20): 2629-2632.
- 16Dogan M, Ozal G, Savas B, et al. Malign peritoneal mesothelioma with nephrotic syndrome. Bratisl Lek Listy. 2012; 113(1): 43-45.
- 17Hermann J, Bajko G, Stajgis M, Szmeja J, Kościński T, Drews M. Fever of unknown origin: a clinical mask of malignant peritoneal mesothelioma. Contemp Oncol (Pozn). 2012; 16(6): 596-599.
- 18Chen L, Huang L, Wang J, Qian Y, Fang L. Malignant peritoneal mesothelioma presenting with persistent high fever. J Zhejiang Univ Sci B. 2011; 12(5): 381-384.
- 19Bani-Hani KE, Gharaibeh KA. Malignant peritoneal mesothelioma. J Surg Oncol. 2005; 91(1): 17-25.
- 20Acherman YI, Welch LS, Bromley CM, Sugarbaker PH. Clinical presentation of peritoneal mesothelioma. Tumori. 2003; 89(3): 269-273.
- 21Nakano T, Fujii J, Tamura S, Hada T, Higashino K. Thrombocytosis in patients with malignant pleural mesotheliomia. Cancer. 1986; 58(8): 1699-1701.
10.1002/1097-0142(19861015)58:8<1699::AID-CNCR2820580820>3.0.CO;2-B CAS PubMed Web of Science® Google Scholar
- 22Stone RL, Nick AM, Mcneish IA, et al. Paraneoplastic thrombocytosis in ovarian cancer. N Engl J Med. 2012; 366(7): 610-618.
- 23Schmitter D, Lauber B, Fagg B, Stahel RA. Hematopoietic growth factors secreted by seven human pleural mesothelioma cell lines: interleukin-6 production as a common feature. Int J Cancer. 1992; 51(2): 296-301.
- 24Judge S, Thomas P, Govindarajan V, Sharma P, Loggie B. Malignant peritoneal mesothelioma: characterization of the inflammatory response in the tumor microenvironment. Ann Surg Oncol. 2016; 23(5): 1496-1500.
- 25Lin RJ, Afshar-Kharghan V, Schafer AI. Paraneoplastic thrombocytosis: the secrets of tumor self-promotion. Blood. 2014; 124(2): 184-187.
- 26Prandoni P, Falanga A, Piccioli A. Cancer and venous thromboembolism. Lancet Oncol. 2005; 6(6): 401-410.
- 27Lee AYY, Levine MN. Venous thromboembolism and cancer: risks and outcomes. Circulation. 2003; 107(23 suppl 1): I17-I21.
- 28Idell S, Pueblitz S, Emri S, et al. Regulation of fibrin deposition by malignant mesothelioma. Am J Pathol. 1995; 147(5): 1318-1329.
- 29Nakano T, Chahinian A, Shinjo M, et al. Interleukin 6 and its relationship to clinical parameters in patients with malignant pleural mesothelioma. Br J Cancer. 1998; 77(6): 907-912.
- 30Fox EA, Kahn SR. The relationship between inflammation and venous thrombosis. A systematic review of clinical studies. Thromb Haemost. 2005; 94(2): 362-365.
- 31Altinbas M, Coskun HS, Er O, et al. A randomized clinical trial of combination chemotherapy with and without low-molecular-weight heparin in small cell lung cancer. J Thromb Haemost. 2004; 2(8): 1266-1271.
- 32Moschcowitz E. An acute febrile pleiochromic anemia with hyaline thrombosis of the terminal arterioles and capillaries: an undescribed disease. 1925. Mt Sinai J Med. 2003; 70(5): 352-355.
- 33George JN. Evaluation and management of patients with thrombotic thrombocytopenic purpura. J Intensive Care Med. 2007; 22(2): 82-91.
- 34Wang J, Cai X, Cheng X, Song P, Jiang S, Gong J. Acute myocardial infarction caused by tumor-associated thrombotic thrombocytopenic purpura: case report. Med Princ Pract. 2014; 23(3): 289-291.
- 35Furlan M, Robles R, Galbusera M, et al. von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome. N Engl J Med. 1998; 339(22): 1578-1584.
- 36Pirrotta MT, Bucalossi A, Forconi F, et al. Thrombotic thrombocytopenic purpura secondary to an occult adenocarcinoma. Oncologist. 2005; 10(4): 299-300.
- 37Nayar MK, Lombard MG, Furlong NJ, McNulty SJ, Hardy KJ, Vora J. Diagnosis and management of nonislet cell tumor hypoglycemia. Endocrinologist. 2006; 16(4): 227-230.
10.1097/01.ten.0000226008.02412.0b Google Scholar
- 38Le Roith D. Insulin-like growth factors. N Engl J Med. 1997; 336(9): 633-640.
- 39Sam AH, Salem V, Ogilvie AJ, Clements MR. Paraneoplastic hypoglycemia—“big” deal. Endocr Pract. 2011; 17(2): 303-305.
- 40Dimitriadis GK, Angelousi A, Weickert MO, Randeva HS, Kaltsas G, Grossman A. Paraneoplastic endocrine syndromes. Endocr Relat Cancer. 2017; 24(6): R173-R190.
- 41Sardiña González C, Martínez Vivero C, López Castro J. Paraneoplastic syndromes review: the great forgotten ones. Crit Rev Oncol Hematol. 2022; 174:103676.
- 42Bodnar TW, Acevedo MJ, Pietropaolo M. Management of non-islet-cell tumor hypoglycemia: a clinical review. J Clin Endocrinol Metab. 2014; 99(3): 713-722.
- 43Ono M, Maeda Y, Koyama N, et al. A case of nonislet cell tumor hypoglycemia associated with malignant mesothelioma requiring a multifaceted approach for optimal glycemic control. Clin Case Rep. 2021; 9(10):e05028.
- 44Gullo D, Sciacca L, Parrinello G, Tomaselli L, Vigneri R. Treatment of hemangiopericytoma-induced hypoglycemia with growth hormone and corticosteroids. J Clin Endocrinol Metab. 1999; 84(5): 1758-1762.
- 45Iglesias P, Díez JJ. Management of endocrine disease: a clinical update on tumor-induced hypoglycemia. Eur J Endocrinol. 2014; 170(4): R147-R157.
- 46Chung J, Henry RR, Chung J. Mechanisms of tumor-induced hypoglycemia with intraabdominal hemangiopericytoma. J Clin Endocrinol Metab. 1996; 81(3): 919-925.
- 47Doi M, Sugiyama T, Izumiyama H, Yoshimoto T, Hirata Y. Clinical features and management of ectopic ACTH syndrome at a single institute in Japan. Endocr J. 2010; 57(12): 1061-1069.
- 48Piasecka M, Larsson M, Papakokkinou E, Olsson L, Ragnarsson O. Is ectopic Cushing's syndrome underdiagnosed in patients with small cell lung cancer? Front Med. 2022; 9:954033.
10.3389/fmed.2022.954033 Google Scholar
- 49Barbosa SLS, Rodien P, Leboulleux S, et al. Ectopic adrenocorticotropic hormone-syndrome in medullary carcinoma of the thyroid: a retrospective analysis and review of the literature. Thyroid. 2005; 15(6): 618-623.
- 50Nimalasena S, Freeman A, Harland S. Paraneoplastic Cushing's syndrome in prostate cancer: a difficult management problem. BJU Int. 2008; 101(4): 424-427.
- 51Alexandraki KI, Grossman AB. The ectopic ACTH syndrome. Rev Endocr Metab Disord. 2010; 11(2): 117-126.
- 52Tucker SC, Coulson IH, Salman W, Kendra JR, Johnson CE. Mesothelioma-associated antiphospholipid antibody syndrome presenting with cutaneous infarction and neuropathy. Br J Dermatol. 1998; 138(6): 1092-1094.
- 53Ruffatti A, Aversa S, Del Ross T, Tonetto S, Fiorentino M, Todesco S. Antiphospholipid antibody syndrome associated with ovarian cancer. A new paraneoplastic syndrome? J Rheumatol. 1994; 21(11): 2162-2163.
- 54Islam MA. Antiphospholipid antibodies and antiphospholipid syndrome in cancer: uninvited guests in troubled times. Semin Cancer Biol. 2020; 64: 108-113.
- 55Miesbach W. Antiphospholipid antibodies and antiphospholipid syndrome in patients with malignancies: features, incidence, identification, and treatment. Semin Thromb Hemost. 2008; 34(3): 282-285.
- 56Salvarani C, Gabriel SE, Michael O'Fallon W, Hunder GG. Epidemiology of polymyalgia rheumatica in Olmsted County, Minnesota, 1970-1991. Arthritis Rheum. 1995; 38(3): 369-373.
- 57Coelho S, Magalhães H, Correia J, Magalhães A, Lourenço P. Polymyalgia rheumatica and pulmonary adenocarcinoma: a case report and literature review. Porto Biomed J. 2017; 2(3): 93-95.
- 58Bojinca V, Janta I. Rheumatic diseases and malignancies. Maedica. 2012; 7(4): 364-371.
- 59Umetsu A, Shimizu T, Iwamoto N, et al. Paraneoplastic syndrome presenting with polymyalgia rheumatica-like accumulations on <sup>18</sup>F-fluorodeoxyglucose-positron emission tomography/computed tomography. Intern Med. 2019; 58(6): 861-864.
- 60Kimura N, Ogasawara T, Asonuma S, Hama H, Sawai T, Toyota T. Granulocyte-colony stimulating factor- and interleukin 6-producing diffuse deciduoid peritoneal mesothelioma. Mod Pathol. 2005; 18(3): 446-450.
- 61Samson M, Audia S, Fraszczak J, et al. Th1 and Th17 lymphocytes expressing CD161 are implicated in giant cell arteritis and polymyalgia rheumatica pathogenesis. Arthritis Rheum. 2012; 64(11): 3788-3798.
- 62Hernández-Rodríguez J. Treatment of polymyalgia rheumatica: a systematic review. Arch Intern Med. 2009; 169(20): 1839-1850.
- 63Candler PM. A follow up study of patients with paraneoplastic neurological disease in the United Kingdom. J Neurol Neurosurg Psychiatry. 2004; 75(10): 1411-1415.
- 64Posner JB. Immunology of paraneoplastic syndromes: overview. Ann NY Acad Sci. 2003; 998: 178-186.
- 65Blum TG, Misch D, Kollmeier J, Thiel S, Bauer TT. Autoimmune disorders and paraneoplastic syndromes in thymoma. J Thorac Dis. 2020; 12(12): 7571-7590.
- 66Thomson DJ, Soni A, Ward M, Jones HW. Simultaneous presentation of myasthenia gravis and mesothelioma. J R Soc Med. 2006; 99(5): 259-260.
- 67Vernino S, Adamski J, Kryzer TJ, Fealey RD, Lennon VA. Neuronal nicotinic ACh receptor antibody in subacute autonomic neuropathy and cancer-related syndromes. Neurology. 1998; 50(6): 1806-1813.
- 68Romi F, Gilhus NE, Aarli JA. Myasthenia gravis: clinical, immunological, and therapeutic advances. Acta Neurol Scand. 2005; 111(2): 134-141.
- 69Souto EB, Lima B, Campos JR, Martins-Gomes C, Souto SB, Silva AM. Myasthenia gravis: state of the art and new therapeutic strategies. J Neuroimmunol. 2019; 337:577080.
- 70Gu D, Liao W, Su Q, Gu J, Chen Y. Primary lung cancer firstly presents as nephrotic syndrome: one case report and literature review. Transl Cancer Res. 2019; 8(8): 2933-2935.
- 71Venzano C, Di Marco E, Garbero M, Forno P, Marchese A, Borghesi R. Nephrotic syndrome associated with pleural mesothelioma. An unusual paraneoplastic event. Recenti Prog Med. 1990; 81(5): 325-326.
- 72Schroeter NJ. Minimal-change nephrotic syndrome associated with malignant mesothelioma. Arch Intern Med. 1986; 146(9): 1834-1836.
- 73Tsukamoto Y, Otsuki T, Hao H, et al. Epithelioid pleural mesothelioma concurrently associated with miliary pulmonary metastases and minimal change nephrotic syndrome—a hitherto undescribed case. Pathol Res Pract. 2015; 211(12): 1014-1019.
- 74Li JYZ, Yong TY, Kuss BJ, Klebe S, Kotasek D, Barbara JAJ. Malignant pleural mesothelioma with associated minimal change disease and acute renal failure. Ren Fail. 2010; 32(8): 1012-1015.
- 75Suzuki S, Toyoshima M, Nihashi F, et al. An autopsy case of malignant pleural mesothelioma associated with nephrotic syndrome. Intern Med. 2014; 53(3): 243-246.
- 76Jhaveri KD, Shah HH, Calderon K, Campenot ES, Radhakrishnan J. Glomerular diseases seen with cancer and chemotherapy: a narrative review. Kidney Int. 2013; 84(1): 34-44.
- 77Taniguchi K, Fujioka H, Torashima Y, Yamaguchi J, Izawa K, Kanematsu T. Rectal cancer with paraneoplastic nephropathy: association of vascular endothelial growth factor. Dig Surg. 2004; 21(5-6): 455-457.
- 78Zell JA, Chang JC. Neoplastic fever: a neglected paraneoplastic syndrome. Support Care Cancer. 2005; 13(11): 870-877.
- 79Kurzrock R. The role of cytokines in cancer-related fatigue. Cancer. 2001; 92(6 suppl): 1684-1688.
10.1002/1097-0142(20010915)92:6+<1684::AID-CNCR1497>3.0.CO;2-Z CAS PubMed Web of Science® Google Scholar
- 80Johnson M. Neoplastic fever. Palliat Med. 1996; 10(3): 217-224.
- 81Liang XL, Su YD, Li XB, et al. Risk factors and prognosis of malignant peritoneal mesothelioma with paraneoplastic syndrome. World J Surg Oncol. 2024; 22(1):29.
